1Data on file, Eli Lilly and Company and/or one of its subsidiaries.
2Verzenio [package insert]. Indianapolis, IN: Eli Lilly and Company; 2021.
3Rugo HS, Huober J, Garcia-Saenz JA, et al. Management of abemaciclib-associated adverse events in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: safety analysis of MONARCH 2 and MONARCH 3. Oncologist. 2021;26(1):e53-e65. http://dx.doi.org/10.1002/onco.13531